Related Experiment Videos
[Value of sustonit in the treatment of patients with stable angina pectoris]
Insights
Sustonit effectively reduced anginal pains and improved left ventricular function in patients with stable angina. This treatment demonstrated significant benefits in exercise capacity and overall cardiac performance.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable angina pectoris is a common cardiovascular condition characterized by chest pain due to myocardial ischemia.
- Effective management of stable angina aims to reduce symptoms, improve exercise tolerance, and enhance left ventricular function.
Purpose of the Study:
- To evaluate the efficacy of Sustonit (mite or forte) in managing symptoms and improving cardiac function in patients with stable angina.
- To assess the impact of Sustonit on exercise capacity and left ventricular performance.
Main Methods:
- A clinical trial involving 40 men with stable angina receiving Sustonit for three weeks.
- Assessment included exercise tests on a cycle ergometer and echocardiography before and after treatment.
- Patient-reported outcomes included anginal pain frequency and nitroglycerin use.
Main Results:
- Sustonit reduced anginal pains in 82.5% of patients.
- Beneficial effects on left ventricular function were observed, including increased mean velocity of circumferential fiber shortening and fewer segmental contractility disturbances.
- Significant improvements in exercise tolerance were noted, with increased work done and working time until submaximal heart rate.
Conclusions:
- Sustonit (mite and forte) is a highly valuable and effective treatment for patients with stable angina.
- The drug improves anginal symptoms, enhances left ventricular function, and increases exercise capacity without significantly affecting heart rate or blood pressure.
Abstract:
The clinical trial was carried out in 40 men with stable angina receiving for three weeks Sustonit mite or forte. Before and after three weeks of the treatment the exercise test was done on cycle ergometer, followed by echocardiography (for evaluation of left ventricular function) noting also the number of anginal pains and the number of nitroglycerin tablets taken as emergency treatment. In the light of the obtained results it was estimated that Sustonit reduced anginal pains in 82.5% of the patients with stable angina, and exerted a beneficial effect on the left ventricular function as evidenced by increased mean velocity of shortening of the circumferential fibres and reduced number of echocardiograms with segmental contractility disturbances in the ventricular septum and posterior wall of the left ventricle after 3 weeks of treatment. Moreover, Sustoinit treatment increased significantly the amount of work done until reaching of submaximal heart rate and working time during submaximal exercise, as well as the greatest workload necessary for reaching of submaximal heart rate. The drug had no significant effect on the heart and arterial blood pressure. Sustonit mite and forte is regarded as highly valuable and effective drug in the treatment of patients with stable angina.